Inhibition of protein kinase Cβ protects against diabetes-induced impairment in arachidonic acid dilation of small coronary arteries

Wei Zhou, Xiao Li Wang, Kathryn G. Lamping, Hon Chi Lee

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

To test the hypothesis that protein kinase C (PKC)β-induced reactive oxygen species (ROS) underlie the vascular dysfunction in diabetes, we examined the effects of (S)-13[(dimethylamino)-methyl]-10,11-14,15-tetrahydro-4,9:16,21- dimetheno-1H,13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadi-azacyclohexadecene-1, 3(2H)-dione (LY333531; LY), a specific PKCβ inhibitor, on arachidonic acid (AA)-mediated dilation in small coronary arteries from streptozotocin-induced diabetic rats. This study was designed to determine whether diabetes impairs AA-induced vasodilation of small coronary arteries and whether this defect could be blunted by dietary treatment with LY. Coronary diameter was measured using videomicroscopy in isolated pressurized vessels. In controls, AA dose dependently dilated coronary arteries, with 1 μM producing 54.7 ± 3.1% and 30 μM producing 72.0 ± 3.0% dilation (n = 9). In diabetic rats, 1 μM AA only produced 31.4 ± 3.8% (n = 8; p < 0.01 versus control) and 30 μM 43.8 ± 3.7% dilation (n = 8; p < 0.001 versus control). Nitroprusside-mediated vasodilations were similar in control and diabetic rats. In contrast, in diabetic rats receiving LY, AA-mediated coronary dilations were normal. In controls, AA-mediated vasodilation was inhibited by miconazole (an inhibitor of cytochrome P450 epoxygenase) and by iberiotoxin (IBTX, an inhibitor of the large conductance Ca2+-activated K+ channel), but miconazole and IBTX had no effects in diabetic vessels. In diabetic rats receiving LY, the effects of miconazole and IBTX were similar to control. Superoxide dismutase restored responses to AA in diabetic vessels but had no effect in vessels from control or diabetic rats on LY. These results suggest that AA-mediated vasodilation in rat coronary arteries are impaired in diabetic rats due to increases in generation of ROS. LY protects against these defects in diabetes through inhibition of PKCβ-mediated production of ROS.

Original languageEnglish (US)
Pages (from-to)199-207
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume319
Issue number1
DOIs
StatePublished - 2006

Fingerprint

Arachidonic Acid
Protein Kinase C
Dilatation
Coronary Vessels
Miconazole
Vasodilation
Reactive Oxygen Species
ruboxistaurin
Calcium-Activated Potassium Channels
Video Microscopy
Protein C Inhibitor
Nitroprusside
Protein Kinase Inhibitors
Streptozocin
Cytochrome P-450 Enzyme System
Superoxide Dismutase
Blood Vessels

ASJC Scopus subject areas

  • Pharmacology

Cite this

Inhibition of protein kinase Cβ protects against diabetes-induced impairment in arachidonic acid dilation of small coronary arteries. / Zhou, Wei; Wang, Xiao Li; Lamping, Kathryn G.; Lee, Hon Chi.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 319, No. 1, 2006, p. 199-207.

Research output: Contribution to journalArticle

@article{31f0081134034350a54e5c5d7f72b528,
title = "Inhibition of protein kinase Cβ protects against diabetes-induced impairment in arachidonic acid dilation of small coronary arteries",
abstract = "To test the hypothesis that protein kinase C (PKC)β-induced reactive oxygen species (ROS) underlie the vascular dysfunction in diabetes, we examined the effects of (S)-13[(dimethylamino)-methyl]-10,11-14,15-tetrahydro-4,9:16,21- dimetheno-1H,13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadi-azacyclohexadecene-1, 3(2H)-dione (LY333531; LY), a specific PKCβ inhibitor, on arachidonic acid (AA)-mediated dilation in small coronary arteries from streptozotocin-induced diabetic rats. This study was designed to determine whether diabetes impairs AA-induced vasodilation of small coronary arteries and whether this defect could be blunted by dietary treatment with LY. Coronary diameter was measured using videomicroscopy in isolated pressurized vessels. In controls, AA dose dependently dilated coronary arteries, with 1 μM producing 54.7 ± 3.1{\%} and 30 μM producing 72.0 ± 3.0{\%} dilation (n = 9). In diabetic rats, 1 μM AA only produced 31.4 ± 3.8{\%} (n = 8; p < 0.01 versus control) and 30 μM 43.8 ± 3.7{\%} dilation (n = 8; p < 0.001 versus control). Nitroprusside-mediated vasodilations were similar in control and diabetic rats. In contrast, in diabetic rats receiving LY, AA-mediated coronary dilations were normal. In controls, AA-mediated vasodilation was inhibited by miconazole (an inhibitor of cytochrome P450 epoxygenase) and by iberiotoxin (IBTX, an inhibitor of the large conductance Ca2+-activated K+ channel), but miconazole and IBTX had no effects in diabetic vessels. In diabetic rats receiving LY, the effects of miconazole and IBTX were similar to control. Superoxide dismutase restored responses to AA in diabetic vessels but had no effect in vessels from control or diabetic rats on LY. These results suggest that AA-mediated vasodilation in rat coronary arteries are impaired in diabetic rats due to increases in generation of ROS. LY protects against these defects in diabetes through inhibition of PKCβ-mediated production of ROS.",
author = "Wei Zhou and Wang, {Xiao Li} and Lamping, {Kathryn G.} and Lee, {Hon Chi}",
year = "2006",
doi = "10.1124/jpet.106.106666",
language = "English (US)",
volume = "319",
pages = "199--207",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Inhibition of protein kinase Cβ protects against diabetes-induced impairment in arachidonic acid dilation of small coronary arteries

AU - Zhou, Wei

AU - Wang, Xiao Li

AU - Lamping, Kathryn G.

AU - Lee, Hon Chi

PY - 2006

Y1 - 2006

N2 - To test the hypothesis that protein kinase C (PKC)β-induced reactive oxygen species (ROS) underlie the vascular dysfunction in diabetes, we examined the effects of (S)-13[(dimethylamino)-methyl]-10,11-14,15-tetrahydro-4,9:16,21- dimetheno-1H,13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadi-azacyclohexadecene-1, 3(2H)-dione (LY333531; LY), a specific PKCβ inhibitor, on arachidonic acid (AA)-mediated dilation in small coronary arteries from streptozotocin-induced diabetic rats. This study was designed to determine whether diabetes impairs AA-induced vasodilation of small coronary arteries and whether this defect could be blunted by dietary treatment with LY. Coronary diameter was measured using videomicroscopy in isolated pressurized vessels. In controls, AA dose dependently dilated coronary arteries, with 1 μM producing 54.7 ± 3.1% and 30 μM producing 72.0 ± 3.0% dilation (n = 9). In diabetic rats, 1 μM AA only produced 31.4 ± 3.8% (n = 8; p < 0.01 versus control) and 30 μM 43.8 ± 3.7% dilation (n = 8; p < 0.001 versus control). Nitroprusside-mediated vasodilations were similar in control and diabetic rats. In contrast, in diabetic rats receiving LY, AA-mediated coronary dilations were normal. In controls, AA-mediated vasodilation was inhibited by miconazole (an inhibitor of cytochrome P450 epoxygenase) and by iberiotoxin (IBTX, an inhibitor of the large conductance Ca2+-activated K+ channel), but miconazole and IBTX had no effects in diabetic vessels. In diabetic rats receiving LY, the effects of miconazole and IBTX were similar to control. Superoxide dismutase restored responses to AA in diabetic vessels but had no effect in vessels from control or diabetic rats on LY. These results suggest that AA-mediated vasodilation in rat coronary arteries are impaired in diabetic rats due to increases in generation of ROS. LY protects against these defects in diabetes through inhibition of PKCβ-mediated production of ROS.

AB - To test the hypothesis that protein kinase C (PKC)β-induced reactive oxygen species (ROS) underlie the vascular dysfunction in diabetes, we examined the effects of (S)-13[(dimethylamino)-methyl]-10,11-14,15-tetrahydro-4,9:16,21- dimetheno-1H,13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadi-azacyclohexadecene-1, 3(2H)-dione (LY333531; LY), a specific PKCβ inhibitor, on arachidonic acid (AA)-mediated dilation in small coronary arteries from streptozotocin-induced diabetic rats. This study was designed to determine whether diabetes impairs AA-induced vasodilation of small coronary arteries and whether this defect could be blunted by dietary treatment with LY. Coronary diameter was measured using videomicroscopy in isolated pressurized vessels. In controls, AA dose dependently dilated coronary arteries, with 1 μM producing 54.7 ± 3.1% and 30 μM producing 72.0 ± 3.0% dilation (n = 9). In diabetic rats, 1 μM AA only produced 31.4 ± 3.8% (n = 8; p < 0.01 versus control) and 30 μM 43.8 ± 3.7% dilation (n = 8; p < 0.001 versus control). Nitroprusside-mediated vasodilations were similar in control and diabetic rats. In contrast, in diabetic rats receiving LY, AA-mediated coronary dilations were normal. In controls, AA-mediated vasodilation was inhibited by miconazole (an inhibitor of cytochrome P450 epoxygenase) and by iberiotoxin (IBTX, an inhibitor of the large conductance Ca2+-activated K+ channel), but miconazole and IBTX had no effects in diabetic vessels. In diabetic rats receiving LY, the effects of miconazole and IBTX were similar to control. Superoxide dismutase restored responses to AA in diabetic vessels but had no effect in vessels from control or diabetic rats on LY. These results suggest that AA-mediated vasodilation in rat coronary arteries are impaired in diabetic rats due to increases in generation of ROS. LY protects against these defects in diabetes through inhibition of PKCβ-mediated production of ROS.

UR - http://www.scopus.com/inward/record.url?scp=33749000621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749000621&partnerID=8YFLogxK

U2 - 10.1124/jpet.106.106666

DO - 10.1124/jpet.106.106666

M3 - Article

C2 - 16861398

AN - SCOPUS:33749000621

VL - 319

SP - 199

EP - 207

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -